STENTYS Starts Clinical Trial to Broaden Portfolio with New Drug …MarketWatch (press release)"Long-term malapposition of drug-eluting stents has been associated with late stent thrombosis, so this randomized trial with the new STENTYS sirolimus-…
Team led by Indian-origin doctor performs feat in Sweden.
InGen BioSciences Group, Exclusive Distributor for Cylex …Sacramento BeeCainelli F., Vento S. Infections and solid organ transplant rejection: a … Using an immune functional assay to differentiate acute cellular rejection from recurrent …and more…
Researchers Demonstrate WGS Potential for Tracking MRSA …GenomeWebMay 23, 2012 / Clinical Sequencing News · Stanford Team Publishes Method for HLA Typing Using HiSeq and MiSeq. May 23, 2012 / Clinical Sequencing News …
Life Technologies Establishes Manufacturing Facility in SingaporeGenomeWebLife Tech Looks to Develop HLA Typing Assays for PGM. April 18, 2012 / Clinical Sequencing News · Macrogen Expands Sequencing Fleet in Preparation for …
Heart failure summit in KeralaIBNLive.comKottayam, June 14 (PTI): A two-day summit on heart failure, first of its kind in Kerala, would begin at Kumarakom here on Saturday. The summit organised by …
World Blood Donor Day 2012: Blood donation dries up in the summerIndia.Com Health“As schools and colleges shut for summer vacation, there is a sharp fall in blood donation camps during summer. The blood banks run out of blood and its …and more …
Zee News`India faces huge blood donation deficit`Zee NewsIndia faces a whopping blood deficit of approximately 30-35 per cent annually.City people still hesitate in blood donationTimes of IndiaVoluntary blood donation need of the hourThe HinduPenang Ho…
( HHV-6 Foundation ) Investigators report that a common, treatable virus was found in a third of infants with prolonged seizures. Many of these infants develop repeat seizures, suffer cognitive declines and go on to develop full-blown epilepsy. An anti…
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment…